Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Entry into a Material Definitive AgreementItem 1.01. Entry into a Material Definitive Agreement.
On September 11, 2017, Natus Medical Incorporated (the “Company”) and Integra LifeSciences Holdings Corporation ("Integra") entered into a definitive Purchase Agreement (the "Purchase Agreement").
to the Purchase Agreement, the Company will acquire certain neurosurgery business assets from Integra in an all cash transaction for $47.5 million.
With current annual revenue of approximately $50 million, the acquisition marks the Company's entry into the $2 billion global neurosurgery market. As part of the transaction, Natus will acquire the global Camino ICP monitoring product line, including its San Diego manufacturing facility, from Integra. The sale also includes the U.S. rights relating to Integra’s fixed pressure shunts, as well as U.S. right to Codman’s DURAFORM® dural graft implant, standard EVD catheters and CSF collection systems.
On September 11, 2017, the Company issued a press release announcing a definitive agreement was signed for the acquisition of neurosurgery assets from Integra. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
It is expected that the acquisition transaction will close in October 2017 after securing regulatory clearance. The acquisition will be funded by cash on hand and available from its credit facility.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press release dated September 11, 2017 announcing the Purchase Agreement. |
NATUS MEDICAL INC ExhibitEX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1Natus to Acquire Neurosurgery Assets from Integra LifeSciences,…To view the full exhibit click here
About Natus Medical Incorporated (NASDAQ:BABY)
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.